The second part of the interview with Guillem Lopez Casasnovas on the organization and financing of the Spanish health care system

Our goal at MTRC is to inform the decision-making of our clients and to support their market access activities. Below is a snapshot of our planned activities for the next two weeks. This can help our existing and prospective clients to better understand the potential scope of our support. From the week of 29th of July, we are planning to work on 21 projects. Review the full list of planned activities in this post.

On June 19, 2024, the Order SND/606/2024, of June 13, came into force. This Order, among other things, creates the Advisory Committee for the Common Package of Benefits in the Area of Genetics.

On June 19, 2024, the Order SND/606/2024, of June 13, came into force. This Order, among other things, amends Annexes I, II, III, VI, and VII of Royal Decree 1030/2006, of September 15, which establishes the Common Package of Benefits of the National Health System and the procedure for its update. The changes mostly concern in-vitro diagnostics, ENT, pulmonary and airways, cardiovascular, and some other fields.

On May 23, 2024, the 2024 working plan was published by the Spanish Network of HTA Agencies (RedETS). Topics in cardiovascular, diagnostic imaging, e-health, endoscopy, ENT, extracorporeal treatments, ICU/OR, in-vitro diagnostics, interventional radiology, men’s health, neurology and neurosurgery, neuromodulation, obstetrics and gynecology, orthopedics, peripheral vascular, pulmonary and airways, radiology, radiotherapy, robotic surgery, spine, surgical procedures, and some other fields are included in the plan.

MTRC developed an analytical White Paper with a summary of key market access elements of EU5 countries, including stakeholders, payment mechanisms, innovative payment schemes, funding, and the role of HTA for in-vitro diagnostic tests.